Clinical Trials
5 trialsNCT06427226 2026-04-17
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
Tanta University
Phase 2 Recruiting
NCT07245069 2025-11-24
Alpaca
University Medical Centre Ljubljana
Phase 2 Recruiting
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT06341842 2024-04-02
PROTECT
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Unknown
NCT05025735 2021-10-19
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Saint Luke's Health System
Phase 2 Unknown